Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s746, 2026. DOI: 10.25251/nq0ynj58. Disponível em: https://skin.dermsquared.com/skin/article/view/4116. Acesso em: 29 apr. 2026.